AstraZeneca (GB:AZN) has released an update.
AstraZeneca announced that its immunotherapy drug Imfinzi did not meet the primary endpoint of disease-free survival in the Phase III ADJUVANT BR.31 trial for early-stage non-small cell lung cancer patients. Despite this setback, the company reaffirmed its commitment to advancing lung cancer treatments, noting Imfinzi’s established role as the standard of care in certain stages of lung cancer. The complete trial results are to be presented at an upcoming medical meeting.
For further insights into GB:AZN stock, check out TipRanks’ Stock Analysis page.
